Vol. 6 No. 9 (2026): September
Reimbursement Reviews

Tafasitamab (Minjuvi)

decorative image of the issue cover

Published September 8, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Tafasitamab (Minjuvi), 200 mg single-use vial, lyophilized powder for solution for IV infusion.
  • Indication: In combination with rituximab and lenalidomide for the treatment of adult patients with Grade 1, 2, or 3a relapsed or refractory follicular lymphoma (FL).